261 related articles for article (PubMed ID: 19644378)
1. B cell depletion in lupus and Sjögren's syndrome: an update.
Coca A; Sanz I
Curr Opin Rheumatol; 2009 Sep; 21(5):483-8. PubMed ID: 19644378
[TBL] [Abstract][Full Text] [Related]
2. Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome.
Coca A; Sanz I
Curr Opin Rheumatol; 2012 Sep; 24(5):451-6. PubMed ID: 22871954
[TBL] [Abstract][Full Text] [Related]
3. Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.
Vossenkämper A; Lutalo PM; Spencer J
Clin Exp Immunol; 2012 Jan; 167(1):7-14. PubMed ID: 22132879
[TBL] [Abstract][Full Text] [Related]
4. Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren's syndrome differ in molecular signatures and treatment perspectives.
Idborg H; Zandian A; Sandberg AS; Nilsson B; Elvin K; Truedsson L; Sohrabian A; Rönnelid J; Mo J; Grosso G; Kvarnström M; Gunnarsson I; Lehtiö J; Nilsson P; Svenungsson E; Jakobsson PJ
Arthritis Res Ther; 2019 Feb; 21(1):62. PubMed ID: 30777133
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
Gottenberg JE; Dörner T; Bootsma H; Devauchelle-Pensec V; Bowman SJ; Mariette X; Bartz H; Oortgiesen M; Shock A; Koetse W; Galateanu C; Bongardt S; Wegener WA; Goldenberg DM; Meno-Tetang G; Kosutic G; Gordon C
Arthritis Rheumatol; 2018 May; 70(5):763-773. PubMed ID: 29381843
[TBL] [Abstract][Full Text] [Related]
6. B-cell depletion and repopulation in autoimmune diseases.
Pers JO; Daridon C; Bendaoud B; Devauchelle V; Berthou C; Saraux A; Youinou P
Clin Rev Allergy Immunol; 2008 Feb; 34(1):50-5. PubMed ID: 18270858
[TBL] [Abstract][Full Text] [Related]
7. Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis.
Narain S; Berman N; Furie R
Curr Opin Rheumatol; 2020 Nov; 32(6):609-616. PubMed ID: 33002950
[TBL] [Abstract][Full Text] [Related]
8. B-cell depletion in autoimmune diseases. Advances in autoimmunity.
Guzman Moreno R
Autoimmun Rev; 2009 Jun; 8(7):585-90. PubMed ID: 19393204
[TBL] [Abstract][Full Text] [Related]
9. Primary Sjögren's syndrome: pathophysiological, clinical and therapeutic advances.
Gottenberg JE
Joint Bone Spine; 2009 Dec; 76(6):591-4. PubMed ID: 19932634
[TBL] [Abstract][Full Text] [Related]
10. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
11. Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date.
Marks SD; Tullus K
Paediatr Drugs; 2007; 9(6):371-8. PubMed ID: 18052407
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
Merrill JT; Neuwelt CM; Wallace DJ; Shanahan JC; Latinis KM; Oates JC; Utset TO; Gordon C; Isenberg DA; Hsieh HJ; Zhang D; Brunetta PG
Arthritis Rheum; 2010 Jan; 62(1):222-33. PubMed ID: 20039413
[TBL] [Abstract][Full Text] [Related]
13. Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy.
Cervera R; Viñas O; Ramos-Casals M; Font J; García-Carrasco M; Sisó A; Ramírez F; Machuca Y; Vives J; Ingelmo M; Burlingame RW
Ann Rheum Dis; 2003 May; 62(5):431-4. PubMed ID: 12695155
[TBL] [Abstract][Full Text] [Related]
14. B-cell depletion in the treatment of lupus nephritis.
Gregersen JW; Jayne DR
Nat Rev Nephrol; 2012 Sep; 8(9):505-14. PubMed ID: 22801948
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of circulating anti-N-methyl-
Tay SH; Fairhurst AM; Mak A
Autoimmun Rev; 2017 Feb; 16(2):114-122. PubMed ID: 27988431
[TBL] [Abstract][Full Text] [Related]
16. B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases.
Sangle SR; Lutalo PM; Davies RJ; Khamashta MA; D'Cruz DP
J Autoimmun; 2013 Jun; 43():55-9. PubMed ID: 23608146
[TBL] [Abstract][Full Text] [Related]
17. [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?].
Atzeni F; Sarzi-Puttini P
Reumatismo; 2010; 62(2):87-8. PubMed ID: 20657883
[No Abstract] [Full Text] [Related]
18. The future of B cell-targeted therapies in Sjögren's syndrome.
Cornec D; Saraux A; Devauchelle-Pensec V; Clodic C; Pers JO
Immunotherapy; 2013 Jun; 5(6):639-46. PubMed ID: 23725286
[TBL] [Abstract][Full Text] [Related]
19. Bibliography. Current world literature. Systemic lupus erythematosus and Sjögren's syndrome.
Curr Opin Rheumatol; 1999 Sep; 11(5):B147-68. PubMed ID: 10503670
[No Abstract] [Full Text] [Related]
20. Primary Sjögren's syndrome and deficiency of ICA69.
Winer S; Astsaturov I; Cheung R; Tsui H; Song A; Gaedigk R; Winer D; Sampson A; McKerlie C; Bookman A; Dosch HM
Lancet; 2002 Oct; 360(9339):1063-9. PubMed ID: 12383988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
